LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

436.84 -3.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

436.84

Максимум

436.84

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
Марж на печалбата	-39.75
Служители	528
EBITDA	-68M -106M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+59.74% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.4B 11B
Предишно отваряне	440.06
Предишно затваряне	436.84

Настроения в новините

By Acuity

50%

141 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

20.02.2026 г., 17:37 ч. UTC

Придобивния, сливания и поглъщания

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

21.02.2026 г., 14:31 ч. UTC

Придобивния, сливания и поглъщания

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

21.02.2026 г., 05:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

20.02.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20.02.2026 г., 22:12 ч. UTC

Печалби

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

20.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

20.02.2026 г., 21:23 ч. UTC

Печалби

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20.02.2026 г., 21:20 ч. UTC

Пазарно говорене

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20.02.2026 г., 21:01 ч. UTC

Придобивния, сливания и поглъщания

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20.02.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20.02.2026 г., 20:17 ч. UTC

Пазарно говорене

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20.02.2026 г., 20:11 ч. UTC

Пазарно говорене

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20.02.2026 г., 19:59 ч. UTC

Пазарно говорене

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20.02.2026 г., 19:58 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20.02.2026 г., 19:49 ч. UTC

Пазарно говорене

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20.02.2026 г., 19:09 ч. UTC

Пазарно говорене

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20.02.2026 г., 19:00 ч. UTC

Пазарно говорене

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20.02.2026 г., 18:28 ч. UTC

Пазарно говорене

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20.02.2026 г., 18:20 ч. UTC

Пазарно говорене

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20.02.2026 г., 18:05 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 18:04 ч. UTC

Пазарно говорене

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20.02.2026 г., 17:38 ч. UTC

Пазарно говорене

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 17:24 ч. UTC

Пазарно говорене

Correction to Treasury Yields Fall Market Talk

20.02.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

20.02.2026 г., 16:53 ч. UTC

Пазарно говорене

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

20.02.2026 г., 16:45 ч. UTC

Пазарно говорене

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

59.74% нагоре

12-месечна прогноза

Среден 694.9 USD 59.74%

Висок 964 USD

Нисък 529 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

141 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.